Prezista Tibotec Pharmaceuticals Ltd. - Treatment for Human Immunodeficiency Virus (HIV)

Prezista, previously known as TMC114, is a protease inhibitor. When co-administered with 100 mg ritonavir (Prezista/rtv) and with other antiretroviral agents, Prezista is indicated for the treatment of human immunodeficiency virus (HIV) infection in antiretroviral treatment-experienced adult patients.

Posted: June 2006

Related Articles:

Prezista (darunavir) FDA Approval History

View comments

Hide
(web3)